Brief transmissions from the neural frontier.
Large retrospective cohort study of 329,000 adults ≥65 years found that two-dose recombinant zoster vaccine (RZV) was associated with a 51% reduction in dementia risk over follow-up. The association remained significant (27% risk reduction) even after controlling for healthy vaccinee bias using Tdap vaccination as a comparator.
Rayens et al, Nat Comm 2026: Recombinant zoster vaccine is associated with a reduced risk of dementia. Read the full paper.
Problem: There is converging evidence that live zoster vaccines reduce dementia risk, but comparable evidence is lacking for the recombinant zoster vaccine (RZV).
Result: RZV vaccination showed a statistically significant 51% reduction in dementia risk (aHR 0.49), with 27% reduction persisting after controlling for healthy vaccinee bias.
Open Questions: The mechanistic basis for this protective effect remains unclear, whether through direct neuroprotection, reduced neuroinflammation, or prevention of subclinical reactivations.